Table 3.

Key messages concerning the BOLERO-2 trial

Compared with exemestane alone, everolimus + exemestane improves median progression-free survival (3.2 months versus 7.8 months) in the treatment of estrogen receptor-positive, HER2-negative advanced breast cancer resistant to nonsteroidal aromatase inhibitor therapy

The benefit is consistent among all prespecified clinical subgroups

Side effects are manageable. Patient education and appropriate dose modification according to existing guidelines are indicated

The most frequent clinically significant side effect is stomatitis. The most medically important side effect is noninfectious pneumonitis

Abbreviations: BOLERO, Breast cancer trials of OraL EveROlimus; HER2, human epidermal growth factor receptor 2.